<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31738367</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>367</StartPage><EndPage>376</EndPage><MedlinePgn>367-376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.3924</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The c9orf72 repeat expansion (c9 or c9orf72RE) confers a survival disadvantage in amyotrophic lateral sclerosis (ALS); its effect on prognosis in frontotemporal dementia (FTD) remains uncertain. Data on prognostic factors in c9orf72RE disorders could inform patient care, genetic counseling, and trial design.</AbstractText><AbstractText Label="OBJECTIVE">To examine prognostic factors in c9ALS, c9FTD, c9ALS-FTD, and atypical phenotypes.</AbstractText><AbstractText Label="DATA SOURCES">The MEDLINE, Embase, Amed, ProQuest, PsychINFO, CINAHL, and LILACS databases were searched between January 2011 and January 2019. Keywords used were c9orf72 and chromosome 9 open reading frame 72. Reference lists, citations of eligible studies, and review articles were also searched by hand.</AbstractText><AbstractText Label="STUDY SELECTION">Studies reporting disease duration for patients with a confirmed c9orf72RE and a neurological and/or psychiatric disorder were included. A second author independently reviewed studies classified as irrelevant by the first author. Analysis began in January 2019.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS">Data were extracted by 1 author; a further author independently extracted 10% of data. Data were synthesized in univariate and multivariable Cox regression and are displayed as hazard ratios (HR) and 95% confidence intervals.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Survival after symptom onset.</AbstractText><AbstractText Label="RESULTS">Overall, 206 studies reporting on 1060 patients were included from 2878 publications identified (c9ALS: n&#x2009;=&#x2009;455; c9FTD: n&#x2009;=&#x2009;296; c9ALS-FTD: n&#x2009;=&#x2009;198; atypical phenotypes: n&#x2009;=&#x2009;111); 197 duplicate cases were excluded. The median (95% CI) survival (in years) differed significantly between patients with c9ALS (2.8 [2.67-3.00]), c9FTD (9.0 [8.09-9.91]), and c9ALS-FTD (3.0 [2.73-3.27]); survival in atypical phenotypes varied substantially. Older age at onset was associated with shorter survival in c9ALS (HR, 1.03; 95% CI, 1.02-1.04; P&#x2009;&lt;&#x2009;.001), c9FTD (HR, 1.04; 95% CI, 1.02-1.06; P&#x2009;&lt;&#x2009;.001), and c9ALS-FTD (HR, 1.02; 95% CI, 1.004-1.04; P&#x2009;=&#x2009;.016). Bulbar onset was associated with shorter survival in c9ALS (HR, 1.64; 95% CI, 1.27-2.08; P&#x2009;&lt;&#x2009;.001). Age at onset and bulbar onset ALS remained significant in multivariable regression including variables indicating potential diagnostic ascertainment bias, selection bias, and reporting bias. Family history, sex, study continent, FTD subtype, or the presence of additional pathogenic sequence variants were not significantly associated with survival. Clinical phenotypes in patients with neuropathologically confirmed frontotemporal lobar degeneration-TDP-43, motor neuron disease-TDP-43 and frontotemporal lobar degeneration-motor neuron disease-TDP-43 were heterogenous and impacted on survival.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Several factors associated with survival in c9orf72RE disorders were identified. The inherent limitations of our methodological approach must be considered; nonetheless, the reported prognostic factors were not significantly associated with the bias indicators examined.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glasmacher</LastName><ForeName>Stella A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Charis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Iona E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31738367</ArticleId><ArticleId IdType="pmc">PMC6865318</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.3924</ArticleId><ArticleId IdType="pii">2755280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256. doi:10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. ; ITALSGEN Consortium . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268. doi:10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss DJ, Poulter M, Beck J, et al. . C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. 2014;82(4):292-299. doi:10.1212/WNL.0000000000000061</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000061</ArticleId><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Pomper JK, Biskup S, Pusk&#xe1;s C, Berg D, Synofzik M. Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol. 2016;263(3)(suppl 2):558-574. doi:10.1007/s00415-016-8021-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8021-7</ArticleId><ArticleId IdType="pubmed">26810719</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JS, Quinzii C, Dunning-Broadbent J, et al. . Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol. 2014;71(6):771-774. doi:10.1001/jamaneurol.2013.5762</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5762</ArticleId><ArticleId IdType="pmc">PMC4051831</ArticleId><ArticleId IdType="pubmed">24733620</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D, Reif A, Dell&#x2019;osso B, et al. . C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol Aging. 2014;35(5):1214.e7-1214.e10. doi:10.1016/j.neurobiolaging.2013.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.12.004</ArticleId><ArticleId IdType="pubmed">24387986</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisler MH, Grant AE, Jones JM, et al. . C9ORF72 expansion in a family with bipolar disorder. Bipolar Disord. 2013;15(3):326-332. doi:10.1111/bdi.12063</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12063</ArticleId><ArticleId IdType="pmc">PMC3660726</ArticleId><ArticleId IdType="pubmed">23551834</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, DeJesus-Hernandez M, Rutherford NJ, et al. . Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122(6):673-690. doi:10.1007/s00401-011-0907-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0907-y</ArticleId><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al. . Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232-240. doi:10.1016/S1474-4422(12)70014-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada LT, Sha SJ. Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease. Alzheimers Res Ther. 2012;4(5):38. doi:10.1186/alzrt141</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt141</ArticleId><ArticleId IdType="pmc">PMC3580395</ArticleId><ArticleId IdType="pubmed">23034079</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, Hornberger M, Irish M, et al. . Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol. 2014;71(3):331-339. doi:10.1001/jamaneurol.2013.6002</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6002</ArticleId><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, et al. ; ITALSGEN and SARDINALS Consortia . Genetic architecture of ALS in Sardinia. Neurobiol Aging. 2014;35(12):2882.e7-2882.e12. doi:10.1016/j.neurobiolaging.2014.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.012</ArticleId><ArticleId IdType="pmc">PMC4252367</ArticleId><ArticleId IdType="pubmed">25123918</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, et al. . Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(2):163-169. doi:10.1136/jnnp-2012-303507</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Corrado L, Castellotti B, et al. ; SLAGEN Consortium . C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiol Aging. 2012;33(10):2528.e7-2528.e14. doi:10.1016/j.neurobiolaging.2012.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.06.008</ArticleId><ArticleId IdType="pubmed">22766072</ArticleId></ArticleIdList></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al. . Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:178.e11-178.e20. doi:10.1016/j.neurobiolaging.2016.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.12.013</ArticleId><ArticleId IdType="pmc">PMC5302213</ArticleId><ArticleId IdType="pubmed">28089114</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Redondo A, Dols-Icardo O, Rojas-Garc&#xed;a R, et al. ; C9ORF72 Spanish Study Group . Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat. 2013;34(1):79-82. doi:10.1002/humu.22211</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22211</ArticleId><ArticleId IdType="pubmed">22936364</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Van Deerlin VM, Robinson JL, et al. . Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 2012;123(6):825-839. doi:10.1007/s00401-012-0970-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0970-z</ArticleId><ArticleId IdType="pmc">PMC3521561</ArticleId><ArticleId IdType="pubmed">22426854</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray S, Race V, Crabb&#xe9; V, et al. . Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiol Aging. 2013;34(12):2890.e7-2890.e12. doi:10.1016/j.neurobiolaging.2013.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.06.009</ArticleId><ArticleId IdType="pubmed">23870417</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, et al. . The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92(3):259-266. doi:10.1111/cge.12973</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12973</ArticleId><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, et al. . Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87(10):1024-1030. doi:10.1212/WNL.0000000000003067</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Borghero G, Restagno G, et al. ; ITALSGEN consortium . Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135(Pt 3):784-793. doi:10.1093/brain/awr366</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr366</ArticleId><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>Miltenberger-Miltenyi G, Concei&#xe7;&#xe3;o VA, Gromicho M, et al. . C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(1):118-120. doi:10.1136/jnnp-2018-318032</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318032</ArticleId><ArticleId IdType="pubmed">29661924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha SJ, Takada LT, Rankin KP, et al. . Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012;79(10):1002-1011. doi:10.1212/WNL.0b013e318268452e</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318268452e</ArticleId><ArticleId IdType="pmc">PMC3430713</ArticleId><ArticleId IdType="pubmed">22875087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al. . Genetic testing in ALS: a survey of current practices. Neurology. 2017;88(10):991-999. doi:10.1212/WNL.0000000000003686</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003686</ArticleId><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94. doi:10.7326/0003-4819-151-4-200908180-00136</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00136</ArticleId><ArticleId IdType="pubmed">19622512</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Blasco H, Besson G, et al. . SOD1 mutation can mask C9orf72 abnormal expansion. Eur J Neurol. 2017;24(4):e24. doi:10.1111/ene.13257</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13257</ArticleId><ArticleId IdType="pubmed">28322003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Bury JJ, Heath PR, et al. . C9ORF72 GGGGCC expanded repeats produce splicing dysregulation which correlates with disease severity in amyotrophic lateral sclerosis. PLoS One. 2015;10(5):e0127376. doi:10.1371/journal.pone.0127376</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127376</ArticleId><ArticleId IdType="pmc">PMC4446097</ArticleId><ArticleId IdType="pubmed">26016851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Koenig L, Beaumont H, et al. . In vivo tau imaging by positron emission tomography in patients with C9ORF72 hexanucleotide repeat expansions. Alzheimers Dement. 2017;13(7):P904-P905. doi:10.1016/j.jalz.2017.07.318</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.07.318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, et al. . Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137(1):27-46. doi:10.1007/s00401-018-1942-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1942-8</ArticleId><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Grinberg Y, et al. . Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol. 2012;69(12):1583-1590. doi:10.1001/archneurol.2012.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.2016</ArticleId><ArticleId IdType="pmc">PMC4005900</ArticleId><ArticleId IdType="pubmed">22964832</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554. doi:10.1212/WNL.51.6.1546</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis: subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci. 1994;124(suppl):96-107. doi:10.1016/0022-510X(94)90191-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34(5):502-508. doi:10.1111/opo.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/opo.12131</ArticleId><ArticleId IdType="pubmed">24697967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, et al. . Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 2013;126(3):401-409. doi:10.1007/s00401-013-1147-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1147-0</ArticleId><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. . Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12(10):978-988. doi:10.1016/S1474-4422(13)70210-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, et al. . Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24(11):3133-3142. doi:10.1093/hmg/ddv064</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv064</ArticleId><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, et al. . Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 2015;130(3):363-372. doi:10.1007/s00401-015-1445-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1445-9</ArticleId><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garc&#xed;a-Redondo A, Rojas-Garc&#xed;a R, et al. . Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2014;23(3):749-754. doi:10.1093/hmg/ddt460</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt460</ArticleId><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Daughrity LM, Heckman MG, et al. ; C9ORF72 Neurofilament Study Group . Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82(1):139-146. doi:10.1002/ana.24980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, et al. . Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623-636. doi:10.1002/acn3.325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.325</ArticleId><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9(8):793-806. doi:10.1016/S1474-4422(10)70159-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70159-9</ArticleId><ArticleId IdType="pmc">PMC2947856</ArticleId><ArticleId IdType="pubmed">20650401</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Warren JD, Fox NC, Rossor MN. Presymptomatic studies in genetic frontotemporal dementia. Rev Neurol (Paris). 2013;169(10):820-824. doi:10.1016/j.neurol.2013.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2013.07.010</ArticleId><ArticleId IdType="pmc">PMC3878569</ArticleId><ArticleId IdType="pubmed">24012408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kansal K, Mareddy M, Sloane KL, et al. . Survival in frontotemporal dementia phenotypes: a meta-analysis. Dement Geriatr Cogn Disord. 2016;41(1-2):109-122. doi:10.1159/000443205</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000443205</ArticleId><ArticleId IdType="pubmed">26854827</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyike CU. What is the life expectancy in frontotemporal lobar degeneration? Neuroepidemiology. 2011;37(3-4):166-167. doi:10.1159/000333347</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000333347</ArticleId><ArticleId IdType="pmc">PMC3953732</ArticleId><ArticleId IdType="pubmed">22056969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. ; Eurals Consortium . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323. doi:10.3109/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Fogh I, Westeneng H-J, et al. . C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(4):281. doi:10.1136/jnnp-2016-314093</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314093</ArticleId><ArticleId IdType="pubmed">27663272</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, et al. . Comparative analysis of C9orf72 and sporadic disease in a large multicenter ALS Population: the effect of male sex on survival of C9orf72 positive patients. Front Neurosci. 2019;13:485-485. doi:10.3389/fnins.2019.00485</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00485</ArticleId><ArticleId IdType="pmc">PMC6534038</ArticleId><ArticleId IdType="pubmed">31156370</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B. A systematic review of behavioural changes in motor neuron disease. Amyotroph Lateral Scler. 2012;13(6):493-501. doi:10.3109/17482968.2012.656652</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.656652</ArticleId><ArticleId IdType="pubmed">22424127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Seelaar H, Josephs KA, et al. . Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol. 2009;66(11):1359-1364. doi:10.1001/archneurol.2009.253</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.253</ArticleId><ArticleId IdType="pmc">PMC2881327</ArticleId><ArticleId IdType="pubmed">19901167</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon EA, Sorenson EJ, Whitwell JL, Knopman DS, Josephs KA. Predicting survival in frontotemporal dementia with motor neuron disease. Neurology. 2011;76(22):1886-1893. doi:10.1212/WNL.0b013e31821d767b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821d767b</ArticleId><ArticleId IdType="pmc">PMC3269075</ArticleId><ArticleId IdType="pubmed">21624986</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Heckman MG, et al. . Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging. 2014;35(10):2421.e13-2421.e17. doi:10.1016/j.neurobiolaging.2014.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.04.016</ArticleId><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Wojtas A, et al. . Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener. 2014;9:38. doi:10.1186/1750-1326-9-38</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-38</ArticleId><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev. 2017;44:117-124. doi:10.1016/j.gde.2017.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.02.008</ArticleId><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman VL, Cooper-Knock J, Connor-Robson N, et al. . Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation. Mol Neurodegener. 2013;8:12. doi:10.1186/1750-1326-8-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-12</ArticleId><ArticleId IdType="pmc">PMC3626718</ArticleId><ArticleId IdType="pubmed">23566336</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al. . Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135(Pt 3):751-764. doi:10.1093/brain/awr365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr365</ArticleId><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S, King A, Troakes C, et al. . p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011;122(6):691-702. doi:10.1007/s00401-011-0911-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0911-2</ArticleId><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conforti FL, Zollino M, et al. ; ITALSGEN Consortium . C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol Aging. 2012;33(8):1848.e15-1848.e20. doi:10.1016/j.neurobiolaging.2012.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.02.011</ArticleId><ArticleId IdType="pmc">PMC3372681</ArticleId><ArticleId IdType="pubmed">22418734</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Boylan KB, Graff-Radford NR, et al. . Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135(Pt 3):765-783. doi:10.1093/brain/aws004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Langenhove T, van der Zee J, et al. . A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012;11(1):54-65. doi:10.1016/S1474-4422(11)70261-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70261-7</ArticleId><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, McLaughlin RL, Byrne S, et al. . Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. J Med Genet. 2013;50(11):776-783. doi:10.1136/jmedgenet-2013-101795</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2013-101795</ArticleId><ArticleId IdType="pmc">PMC3812897</ArticleId><ArticleId IdType="pubmed">23881933</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, et al. . Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77(1):100-113. doi:10.1002/ana.24306</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24306</ArticleId><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, et al. . Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126(6):859-879. doi:10.1007/s00401-013-1181-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1181-y</ArticleId><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L, Rossi G, Glionna M, et al. . C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study. [Erratum]. J Alzheimers Dis. 2015;45(1):319. doi:10.3233/JAD-159001</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-159001</ArticleId><ArticleId IdType="pubmed">25737153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaivorinne AL, Bode MK, Paavola L, et al. . Clinical characteristics of C9ORF72-linked frontotemporal lobar degeneration. Dement Geriatr Cogn Dis Extra. 2013;3(1):251-262. doi:10.1159/000351859</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351859</ArticleId><ArticleId IdType="pmc">PMC3776392</ArticleId><ArticleId IdType="pubmed">24052799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Campoy O, &#xc1;vila-Polo R, Grau-Rivera O, et al. . Systematic screening of Ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation. J Neuropathol Exp Neurol. 2018;77(8):703-709. doi:10.1093/jnen/nly047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly047</ArticleId><ArticleId IdType="pubmed">29889265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>